The association ARMGHM

The association ARMGHM - Atlas Génétique des Cancers - is a non-profit association (french law 1901), whose goal is to host and handle the Atlas of Genetics and Cytogenetics in Oncology and Haematology (AtlasGeneticsOncology.org), to facilitate the editorial process and to permit the circulation of its content.

Built up in 1993 by Doctor Jean-Loup Huret, founder of the Atlas, the association has been chaired by Doctor Franck Viguié. Jean Loup Huret is now the chairman. Hossein Mossafa is vice-president of the association. The association has also a Scientific Board and the Atlas an Editorial Bard of more than 40 high level researchers and clnincians from various countries over the world.

 

Executive Board

Bureau of the Executive Board

 

 

 

Dr Jean-Loup Huret, MD, PhD,
President of the association,

Honorary Associate Professor and Consultant of the French Universities

Chief Editor of the Atlas
This email address is being protected from spambots. You need JavaScript enabled to view it. and
This email address is being protected from spambots. You need JavaScript enabled to view it. and
This email address is being protected from spambots. You need JavaScript enabled to view it. and
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Hossein Mossafa, PhD,
Vice-President of the association,


Geneticist in Onco-Hematology, CERBA Laboratory.
Martine Jammet
Treasurer and Secretary of the association

President of JMFret, Vice President of Polyglotta,
Member of the chamber of commerce and industry of Vienne,
City Councillor of Poitiers
Dr Franck Viguié, MD,
Past President of the association,

Associate Professor and Consultant, University of Paris and CHU Saint Antoine

 

Members of the Executive Board

 
François Desangles,
Philippe Dessen,
Bernard Drochon,
Jean Loup Huret,
Martine Jammet,
Philippe Misserey,
Hossein Mossafa,
Jean-Marie Nicolas,
Franck Viguié,
Lucienne Michaux, representing te Belgian Society of Human Genetics (BeSHG), Presidente of the Belgian Cytogenetics Group in Haematology and Oncology (BCGHO)
Dominique Penther, representing the Association des Cytogénéticiens de Langue Française (ACLF), member of the Board of the Groupe Francophone de Cytogénétique Hématologique (GFCH)

 

 

Editorial Team

 

The association has employed 5 collaborators full time, each holder of a MSc or a PhD, who have managed the Atlas for years with the Editor, who acknowledge their excellent work:

Mohammad Ahmad,
Mélanie Arsaban,
Anne Malo,
Carol Moreau,
Vanessa Le Berre


 

ARMGHM

Official declaration in prefecture : 15-06-1993
n° Siret : 392 427 381 00018
n° Siren : 392 427 381
n° URSSAF : 860 200 231151
n° ASSEDIC : 39133439X8602
code NAF ("code APE"): 7219Z

 

Addresses of the ARMGHM

ARMGHM, Chez Docteur Jean Loup Huret, 10 rue des Treilles, Masseuil, F-86190 Quinçay, Fance.
Or
ARMGHM, Chez Docteur Jean Loup Huret, Faculté de Médecine, 6 rue de la Milétrie, BP 199, F-86034 Poitiers, Fance.

 

Donate now

  • by credit card, on our platform for secure online payment using PayPal :

Donate (in Euros)

Donate (in US Dollars)

 


 

Program

Enrichment with more cards

Development of the research side

- The Atlas participates in research on cancer epidemiology.

- The Atlas is part of the genome project. It is orientated towards the genome and may serve as a portal for many applications, from probes resources to genome sequences. At a time where maturation therapies and other oncogene-targeted therapies are being developed, the Atlas and its links make sense in the bioinformatics field.

Diagnostic and therapeutic decision aid

The Atlas helps the clinician in the diagnostic and in the patient treatment process: the iconography of chromosome anomalies can be compared by the cytogeneticist with his findings in a given patient, guiding his diagnosis. Next step, the clinician with a cytogenetic diagnosis may be helped by the description of the associated disease. In any case, the clinician ignores the prognostic associated with the chromosome findings in many cases (there are more than 600 leukemias!), and the Atlas would guide his treatment decision: a bone marrow graft may kill, it should be reserved for highly aggressive leukemias, and that risk must not be taken when the leukaemia would be cured in any case. The Atlas is indispensable in particular in rare diseases (and rare diseases, because they are numerous, are frequent). We must continue to develop this part.

Informatics developments

Atlas web site becoming a true database - from old html to xml: the Atlas is supported by an ancient html system, made in 1997, at a time where Internet was a starting technology (we were one of the pioneers !). Systems have evolved, since. A modern data base will soon replace our old html.

Enhancement of the Atlas position in the scientific literature world:

We have therefore developed an 'electronic journal' version of the Atlas, comprising 2 154 articles in 87 issues from 1998 making 7 169 pages. See: http://documents.irevues.inist.fr/handle/2042/15655 .